

## 【Luncheon Symposium 9-2】

### **Evocalcet: A New Calcimimetics Landing in Taiwan**

Jiann-Der Lee

Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital

Evocalcet, an advanced calcimimetic, has emerged as a promising treatment for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients undergoing hemodialysis. By targeting the calcium-sensing receptor (CaSR), evocalcet effectively reduces parathyroid hormone (PTH) secretion and parathyroid gland proliferation, offering a novel therapeutic approach. Clinical trials, including head-to-head comparisons with cinacalcet, demonstrate non-inferior efficacy of evocalcet in reducing PTH levels while significantly reducing gastrointestinal (GI)-related adverse events, a common limitation of earlier calcimimetics.

The ORCHESTRA trial and other studies highlight evocalcet's comparable performance to cinacalcet in achieving target PTH levels, even in severe SHPT cases. Transitioning patients from cinacalcet to evocalcet was associated with a well-tolerated and effective outcome, with dosage adjustments mitigating transient PTH increases. Moreover, evocalcet demonstrates better patient compliance due to fewer GI side effects and improved bioavailability.

Long-term studies affirm evocalcet's efficacy and safety, with 87.6% of patients achieving target PTH levels at 52 weeks. Its ability to manage SHPT with fewer side effects positions evocalcet as a central therapy for SHPT management in CKD patients. This evidence underscores evocalcet's potential to enhance clinical outcomes and quality of life for CKD patients.

